4D Molecular TherapeuticsFDMT
About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Employees: 201
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
2% less funds holding
Funds holding: 146 [Q1] → 143 (-3) [Q2]
5.56% less ownership
Funds ownership: 119.29% [Q1] → 113.73% (-5.56%) [Q2]
35% less capital invested
Capital invested by funds: $1.89B [Q1] → $1.23B (-$656M) [Q2]
74% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $4.54M
75% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 1 (-3) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Chardan Capital Geulah Livshits 24% 1-year accuracy 7 / 29 met price target | 396%upside $39 | Buy Maintained | 19 Sept 2024 |
Leerink Partners Mani Foroohar 38% 1-year accuracy 3 / 8 met price target | 357%upside $36 | Outperform Reiterated | 19 Sept 2024 |
HC Wainwright & Co. Matthew Caufield 65% 1-year accuracy 15 / 23 met price target | 357%upside $36 | Buy Reiterated | 19 Sept 2024 |
Financial journalist opinion
Based on 22 articles about FDMT published over the past 30 days
